Pharma's Big Role in Cardio-Oncology  episode artwork

EPISODE · Aug 16, 2022 · 33 MIN

Pharma's Big Role in Cardio-Oncology

from All Things Cardio-Oncology · host International Cardio-Oncology Society

The Leaders of the IC-OS Pharmacy Working Group, Heather N. Moore (PharmD, BCOP, CPP, Clinical Oncology Pharmacist, Breast Oncology, Duke University Medical Center) and Craig Beavers (PharmD, Assistant Professor of Pharmacy Science at the University of Kentucky), discuss the pharmacist's role in caring for cardio-oncology patients and how to implement their assistance in cardio-oncology treatment based on their experience in this scenario.   1. Bringing the pharmacist to the cardio-oncology team makes a more substantial work group to ensure the best assistance to our patients. 2. Having the pharmacist in the working group participating actively in the clinical decisions and helping plan the patient’s next steps can improve tolerance to the treatment, fewer side effects from the drug, and fewer worst interactions between the chronic medications and the oncologic treatment based on the drug profile of each patient. 3. Improving treatment maintenance with the presence of a pharmacist specialized in cardio-oncology, with early recognition of cardiotoxicity and how to modify the therapy to ensure the best treatment, either changing the time of infusion or route of administration, or physical formulation 4. Stimulating new research about new oncology therapies to understand better drug profiles, side effects, pharmacodynamics, and medication interactions. Supplementary material Yaseen I, Farhan H, et al. INTERVENTIONS BY THE CARDIOLOGY CLINICAL PHARMACIST AT THE CARDIO-ONCOLOGY CLINIC. J Am Coll Cardiol. 2022 Mar, 79 (9_Supplement) 2186. https://doi.org/10.1016/S0735-1097(22)03177-1 Yaseen IF and Farhan HA (2022) Cardiovascular drug interventions in the cardio-oncology clinic by a cardiology pharmacist: ICOP-Pharm study. Front. Cardiovasc. Med. 9:972455. doi: 10.3389/fcvm.2022.972455 Campia U, Moslehi J, Amiri-Kordestani L, Et. Al. Cardio-Oncology: Vascular And Metabolic Perspectives A Scientific Statement From The American Heart Association. Circulation. 2019;139:E579–E602 Armenian SH, Lacchetti C, Barac A, Et Al. Prevention And Monitoring Of Cardiac Dysfunction In Survivors Of Adult Cancers: American Society Of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017;35:893-911 Show Notes Provided by: Alana de Quadros Schroeder, MDHospital Cardiologist Hospital Moinhos de Vento Cardiology Department 

Episode metadata supplied by the publisher feed · Published Aug 16, 2022

Embed this episode

NOW PLAYING

Pharma's Big Role in Cardio-Oncology

0:00 33:09

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of All Things Cardio-Oncology?

This episode is 33 minutes long.

When was this All Things Cardio-Oncology episode published?

This episode was published on August 16, 2022.

Can I download this All Things Cardio-Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!